139 related articles for article (PubMed ID: 12405266)
21. Antibody therapeutics, antibody engineering, and the merits of protein stability.
Demarest SJ; Glaser SM
Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
[TBL] [Abstract][Full Text] [Related]
22. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells.
Jannot CB; Beerli RR; Mason S; Gullick WJ; Hynes NE
Oncogene; 1996 Jul; 13(2):275-82. PubMed ID: 8710366
[TBL] [Abstract][Full Text] [Related]
23. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
24. Intrabody and Parkinson's disease.
Zhou C; Przedborski S
Biochim Biophys Acta; 2009 Jul; 1792(7):634-42. PubMed ID: 18834937
[TBL] [Abstract][Full Text] [Related]
25. Antibody phage display applications for nuclear medicine imaging and therapy.
Winthrop MD; Denardo GL; Denardo SJ
Q J Nucl Med; 2000 Sep; 44(3):284-95. PubMed ID: 11105591
[TBL] [Abstract][Full Text] [Related]
26. Designer genes: recombinant antibody fragments for biological imaging.
Wu AM; Yazaki PJ
Q J Nucl Med; 2000 Sep; 44(3):268-83. PubMed ID: 11105590
[TBL] [Abstract][Full Text] [Related]
27. Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach.
Lehmann A; Wixted JH; Shapovalov MV; Roder H; Dunbrack RL; Robinson MK
MAbs; 2015; 7(6):1058-71. PubMed ID: 26337947
[TBL] [Abstract][Full Text] [Related]
28. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery.
Hedley SJ; Auf der Maur A; Hohn S; Escher D; Barberis A; Glasgow JN; Douglas JT; Korokhov N; Curiel DT
Gene Ther; 2006 Jan; 13(1):88-94. PubMed ID: 16107860
[TBL] [Abstract][Full Text] [Related]
29. [Progress of research on genetic engineering antibody and its application in prevention and control of parasitic diseases].
Yao Y; Yu CX
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2013 Aug; 25(4):413-6. PubMed ID: 24358756
[TBL] [Abstract][Full Text] [Related]
30. Synopsis of new antiangiogenetic factors, mutation compensation agents, and monoclonal antibodies in target therapies of breast cancer.
Grammatikakis I; Zervoudis S; Kassanos D
J BUON; 2010; 15(4):639-46. PubMed ID: 21229623
[TBL] [Abstract][Full Text] [Related]
31. Genetically engineered antibodies: progress and prospects.
Wright A; Shin SU; Morrison SL
Crit Rev Immunol; 1992; 12(3-4):125-68. PubMed ID: 1476621
[TBL] [Abstract][Full Text] [Related]
32. Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed within the intracellular environment (Intrabody).
Heng BC; Cao T
Med Hypotheses; 2005; 64(6):1105-8. PubMed ID: 15823695
[TBL] [Abstract][Full Text] [Related]
33. Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy.
Afanasieva TA; Wittmer M; Vitaliti A; Ajmo M; Neri D; Klemenz R
Gene Ther; 2003 Oct; 10(21):1850-9. PubMed ID: 12960975
[TBL] [Abstract][Full Text] [Related]
34. Genetic, cellular and immune approaches to disease therapy: past and future.
Nabel GJ
Nat Med; 2004 Feb; 10(2):135-41. PubMed ID: 14760423
[TBL] [Abstract][Full Text] [Related]
35. Isolating and engineering human antibodies using yeast surface display.
Chao G; Lau WL; Hackel BJ; Sazinsky SL; Lippow SM; Wittrup KD
Nat Protoc; 2006; 1(2):755-68. PubMed ID: 17406305
[TBL] [Abstract][Full Text] [Related]
36. A universal strategy for stable intracellular antibodies.
Shaki-Loewenstein S; Zfania R; Hyland S; Wels WS; Benhar I
J Immunol Methods; 2005 Aug; 303(1-2):19-39. PubMed ID: 16045924
[TBL] [Abstract][Full Text] [Related]
37. Renal transfer of genetically engineered cells.
Kitamura M
J Am Soc Nephrol; 2000 Nov; 11 Suppl 16():S154-8. PubMed ID: 11065349
[TBL] [Abstract][Full Text] [Related]
38. The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases.
Cardinale A; Biocca S
Trends Mol Med; 2008 Sep; 14(9):373-80. PubMed ID: 18693139
[TBL] [Abstract][Full Text] [Related]
39. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers.
Jiang M; Shi W; Zhang Q; Wang X; Guo M; Cui Z; Su C; Yang Q; Li Y; Sham J; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6179-85. PubMed ID: 17062695
[TBL] [Abstract][Full Text] [Related]
40. The biotechnology and applications of antibody engineering.
Rapley R
Mol Biotechnol; 1995 Apr; 3(2):139-54. PubMed ID: 7620975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
